Related Experiment Video
Updated: May 5, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and
Bhavya Bhutani1, Vyoma Sharma1, Nirmal Kumar Ganguly1
1Department of Biotechnology and Research, Sir Ganga Ram Hospital, New Delhi 110060, India.
Purpose:
Despite current technological advancements in the treatment of glioma, immediate alleviation of symptoms can be catered by therapeutic modalities, including surgery, chemotherapy, and combinatorial radiotherapy that exploit aberrations of glioma. Additionally, a small number of target antigens, their heterogeneity, and immune evasion are the potential reasons for developing targeted therapies. This oncologic milestone has catalyzed interest in developing immunotherapies against Glioblastoma to improve overall survival and cure patients with high-grade glioma. The next-gen CAR-T Cell therapy is one of the effective immunotherapeutic strategies in which autologous T cells have been modified to express receptors against GBM and it modulates cytotoxicity.
Methods:
In this review article, we examine preclinical and clinical outcomes, and limitations as well as present cutting-edge techniques to improve the function of CAR-T cell therapy and explore the possibility of combination therapy.
Findings:
To date, several CAR T-cell therapies are being evaluated in clinical trials for GBM and other brain malignancies and multiple preclinical studies have demonstrated encouraging outcomes.
Implications:
CAR-T cell therapy represents a promising therapeutic paradigm in the treatment of solid tumors but a few limitations include, the blood-brain barrier (BBB), antigen escape, tumor microenvironment (TME), tumor heterogeneity, and its plasticity that suppresses immune responses weakens the ability of this therapy. Additional investigation is required that can accurately identify the targets and reflect the similar architecture of glioblastoma, thus optimizing the efficiency of CAR-T cell therapy; allowing for the selection of patients most likely to benefit from immuno-based treatments.
Insights
CAR-T cell therapy shows promise for glioblastoma, but challenges like the blood-brain barrier and tumor heterogeneity require further research for effective treatment.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioma treatment faces challenges due to tumor heterogeneity and immune evasion.
- Targeted therapies are being developed to address these limitations.
Purpose of the Study:
- To review the potential of Chimeric Antigen Receptor T-cell (CAR-T) therapy for glioblastoma.
- To explore strategies for improving CAR-T cell efficacy and combination therapies.
Main Methods:
- Review of preclinical and clinical outcomes of CAR-T cell therapy for brain malignancies.
- Examination of techniques to enhance CAR-T cell function and combination strategies.
Main Results:
- Multiple preclinical studies show encouraging results for CAR-T cell therapy in glioblastoma.
- Several CAR-T cell therapies are currently under evaluation in clinical trials.
Conclusions:
- CAR-T cell therapy is a promising approach for solid tumors, including glioblastoma.
- Limitations such as the blood-brain barrier, antigen escape, and tumor microenvironment need to be overcome.
- Further research is needed to optimize CAR-T cell therapy and identify suitable patient candidates.
More Related Videos
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
